ROCHE DIAGNOSTICS GMBH

Their core work

Roche Diagnostics is the diagnostics division of the Roche Group, one of the world's largest pharmaceutical and diagnostics companies, headquartered in Mannheim, Germany. Their core business is developing and manufacturing in-vitro diagnostic tests, instruments, and digital health solutions used in hospitals, laboratories, and clinical research worldwide. In H2020, they primarily contributed industry expertise and training environments to Marie Skłodowska-Curie research training networks, hosting early-stage researchers in areas spanning cancer immunotherapy, epigenetics, and precision medicine. Their participation reflects a strategic interest in scouting emerging research talent and staying connected to academic advances in diagnostics-relevant fields.

What they specialise in

How they've shifted over time

In the earlier period (2015–2018), Roche Diagnostics engaged in cancer-focused training networks (GlyCoCan, IMMUTRAIN) and smart systems integration support (inSSIght), reflecting broad participation across health and digital sectors. From 2019 onward, their focus sharpened toward data-driven health — particularly machine learning for precision medicine (MLFPM2018) and IoT-based instrument maintenance (VIMS). This shift mirrors the broader diagnostics industry trend of embedding AI and digital tools into clinical workflows and device management.

Roche Diagnostics is moving toward AI and data science applications in clinical diagnostics, making them an increasingly relevant partner for projects at the intersection of machine learning and personalized health.

How they like to work

Roche Diagnostics never led an H2020 consortium — they consistently joined as a partner or third party, which is typical for large corporates contributing industry infrastructure and mentorship rather than driving academic research agendas. With 76 unique partners across 16 countries, they operate as a well-connected but selective industry participant, primarily joining MSCA training networks where they host doctoral researchers. This makes them a reliable industry host for training-oriented projects but not a candidate to coordinate or drive project management.

Roche Diagnostics collaborated with 76 unique partners across 16 countries through just 6 projects, reflecting the large consortium sizes typical of MSCA training networks. Their network spans a broad European footprint with no single geographic concentration beyond their German home base.

What sets them apart

As a global diagnostics leader, Roche brings unmatched industry-scale validation environments for translational research — moving biomarker discoveries from the lab toward commercial diagnostic tests. Few H2020 industry partners can offer comparable access to real-world IVD platforms, regulatory pathway experience, and clinical data infrastructure. For consortium builders, Roche's name also adds significant credibility and signals strong industry relevance to evaluators.

Highlights from their portfolio

• IMMUTRAIN
  Largest direct EC contribution (€249K) to Roche in this portfolio, focused on the commercially critical field of cancer immunotherapy training.
• MLFPM2018
  Represents Roche's strategic pivot toward machine learning in precision medicine — a 5-year project running through 2024, signaling sustained commitment.
• GlyCoCan
  Directly aligned with Roche's diagnostics core: developing improved colorectal cancer diagnostics through glycosylation biomarkers.